Emerging Endometrial Cancer Treatments | Promising Data and Challenges
Emerging Endometrial Cancer Treatments | Promising Data and Challenges from Patient Empowerment Network on Vimeo.
What is the latest in endometrial cancer treatment updates? Expert Dr. Ebony Hoskins shares updates from the RUBY study and one NRG study and provides advice for patients.
Dr. Ebony Hoskins is a board-certified gynecologic oncologist at MedStar Washington Hospital Center and assistant professor of Clinical Obstetrics and Gynecology at Georgetown University Medical Center.
“…if someone’s diagnosed with endometrial cancer, ‘Am I a candidate for a clinical trial to be a part of this new frontier, if you will, for endometrial cancer?’”
Download Guide | Descargar Guía en Español
See More from [ACT]IVATED Endometrial Cancer
Endometrial Cancer Treatment Options for Patients to Consider
What Endometrial Cancer Patients Should Know About Clinical Trials
Dr. Hoskins, what endometrial cancer data and studies coming out of major medical conferences are you most excited about? And can you speak to those kinks and challenges or promises of emerging treatments?
Dr. Ebony Hoskins:
Well, Mikki, I’m very excited. The SGO 2023 in Tampa, Florida, we had new data that came out from one of the NRG studies as well as another study called the RUBY Study. And both were looking at up-front carboplatin (Paraplatin) and paclitaxel (Abraxane) with the addition of immunotherapy. And we saw improved progression-free survival. So that means when the disease is no longer there, how long are patients living without it recurring, and that has increased. So this is a big deal.
And then one of the studies showed again, the data is still maturing so it’s not completely out there yet. So we still have to wait on it, but there may be improved overall survival. And that’s kind of one of the study goals that we always want to do is improve overall survival. So I’m excited about that. There was also some new data looking at whether up-front patients with advanced endometrial cancer, whether they are treated with systemic chemotherapy versus systemic chemotherapy and radiation.
And this is a long ongoing survival data that said, patients basically did equally well with just chemotherapy alone without the addition of radiation. So that I think is very interesting, because we use radiation and chemotherapy in patients with advanced endometrial cancer. That certainly doesn’t mean that it’s not an option, just means that it may need to be more tailored and discussed and discussed with our radiation oncology colleagues.
In terms of what the challenges are, I think immunotherapy is a game changer. But it’s also what I use in terms of second-line treatment. So now I’m using it up front. What happens if a patient recurs while on it? What am I going to do now? That’s my question. What am I going to do next? And I’m not too worried because there are new treatment options that are out. Again, they are not necessarily standard now, but they’re ongoing in clinical trials. So I’m not too worried. But definitely some questions that cross my mind. My activation tip for this for patients is if someone’s diagnosed with endometrial cancer, “Am I a candidate for a clinical trial to be a part of this new frontier, if you will, for endometrial cancer?”